NIMBLE (National Institute for Innovation in Manufacturing Biopharmaceuticals) announcement and tour of the facilities of DBI (Delaware Biotechnology Institute), Friday, December 16th, 2016 with Chris Coons, Tom Carper, John Carney, Willie May-NIST Director and Under Secretary of Commerce and Penny Pritzker-Secretary of Commerce.
Secretary of Commerce Penny Pritzker announces the National Institute for Innovation in Manufacturing Biopharmaceuticals.
Secretary of Commerce Penny Pritzker visited the University of Delaware today, where she announced a new institute to advance U.S. leadership in pharmaceutical manufacturing. The Newark-based National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) will be the 11th Manufacturing USA Institute. Biopharmaceuticals are prescription drugs made with living cells. Most drugs are chemistry-based and far easier to produce. The biopharmaceutical category includes vaccines, cancer drugs and drugs to treat autoimmune diseases, as well as emerging drugs for cell and gene therapies. The institute will focus on bringing safe drugs to market faster and on developing workforce training. The biopharmaceutical field has a negative unemployment rate, with more jobs available than there are qualified workers. A team of more than 150 companies, educational institutions, nonprofits and state governments will operate NIIMBL under a newly formed nonprofit. Expected total investment from all stakeholders totals $250 million, including $70 million of federal investment. The University of Delaware will handle administrative duties for the institute in partnership with the Commerce Department’s National Institute of Standards and Technology (NIST).